Newsroom
Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has successfully signed a new syndicated revolving credit facility with a group of 34 core relationship banks.
Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has agreed to issue bonds with an aggregate principal amount of USD 1.5 billion across two tranches.
Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has filed the annual report 2020 on form 20-F with the U.S. Securities and Exchange Commission (SEC).
Throughout 2020, Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, reported COVID-19 affecting patients with advanced kidney disease and, in particular, the severity of illness resulting in an increased mortality.
